Printer Friendly

BRISTOL-MYERS SQUIBB COMPANY INTRODUCES PROHANCE(R)

 PRINCETON, N.J., Nov. 17 ~PRNewswire~ -- Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration has cleared ProHance(R) (Gadoteridol Injection) for marketing in the United States.
 ProHance is the first non-ionic, macrocyclic magnetic resonance imaging (MRI) contrast agent available to aid in the diagnosis of central nervous system disorders.
 ProHance is indicated for MRI contrast enhancement of the brain, spine and surrounding tissues, resulting in improved visualization (compared with unenhanced MRI) of lesions with abnormal blood circulation or those thought to cause a disruption of the normal blood- brain barrier.
 ProHance is recommended for use at 0.1 mmol~kg administered as a rapid intravenous infusion or bolus. However, in patients suspected of having cerebral metastases or other poorly enhancing lesions, in the presence of negative or equivocal scans, after 0.1 mmol~kg injection, at the clinician's discretion, a second dose of 0.2 mmol~kg can be administered up to 30 minutes after the first dose for further evaluation. This provides physicians with the widest range of dosing options available for an MRI contrast agent.
 In a clinical study of 411 patients, researchers found that MR images enhanced with ProHance (Gadoteridol Injection) at a dose of 0.1 mmol~kg provided more diagnostic information than unenhanced images in 70 percent of brain studies and 59 percent of spinal studies.
 A clinical trial involving 68 patients highly suspected of cerebral metastatic disease revealed that the injection of a cumulative administered dose of 0.3 mmol~kg of ProHance allowed physicians to detect lesions more clearly in select patients, compared with a dose of 0.1 mmol~kg of ProHance.
 In clinical studies, ProHance has been shown to be well-tolerated with a low incidence of side effects at all recommended dosing options.
 MRI is the most rapidly growing of the diagnostic imaging modalities. It is used primarily in the diagnosis of central nervous system disorders, including tumor, stroke, multiple sclerosis, epilepsy and spinal disorders.
 Bristol-Myers Squibb Company said it expects that ProHance will gain widespread usage in this exciting new technology. ProHance will be available in November 1992.
 ProHance is marketed by Squibb Diagnostics, a Bristol-Myers Squibb company and a leader in diagnostic contrast agents and radiopharmaceuticals. Bristol-Myers Squibb is a research-based, diversified health care company whose principal businesses are pharmaceuticals, consumer products, nutritionals and medical devices. It is among the world's leading makers of cardiovascular, anticancer, anti-infective, central nervous system and dermatological drug therapies, diagnostic agents and non-prescription medications.
 ~delval~
 -0- 9~22~92
 ~CONTACT: Patrick D. Donohue of Bristol-Myers Squibb, 609-252-5685, or Karen Cohen of GTFH Public Relations, 212-886-3117, for Bristol-Myers Squibb~
 (BMY)


CO: Bristol-Myers Squibb Company; Squibb Diagnostics ST: New Jersey IN: MTC SU: PDT

MK-MP -- PH004 -- 1708 11~17~92 09:44 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 17, 1992
Words:464
Previous Article:ICI AND MONSANTO SETTLE PATENT DISPUTE ON SAFENERS AND CONCLUDE REGULATORY AND PRODUCTION AGREEMENTS ON ACETOCHLOR
Next Article:PEACHTREE FIBEROPTICS, INC. COMPLETES INITIAL PUBLIC OFFERING
Topics:


Related Articles
BRISTOL-MYERS SQUIBB ANNOUNCES AGREEMENT WITH SCHERING AG
BRISTOL-MYERS SQUIBB APPOINTS WESLEY M. THOMPSON PRESIDENT OF BRISTOL-MEYERS INTERNATIONAL
BRISTOL-MYERS SQUIBB NAMES RICHARD H. MALYAN SENIOR VICE PRESIDENT, INTERNATIONAL BUSINESS DEVELOPMENT
BRISTOL-MYERS SQUIBB AND AKRIHIN CHEMICAL DEDICATE PHARMACEUTICAL MANUFACTURING OPERATION
BRISTOL-MYERS SQUIBB, AXION PHARMACEUTICALS FORM JOINT VENTURE; CANCER DRUG DISTRIBUTION NETWORK ADDRESSES CRITICAL COST-CONTAINMENT NEEDS
BRISTOL-MYERS SQUIBB COMPANY ANNOUNCES IN-LICENSING AGREEMENT FOR GASTROINTESTINAL CONTRAST AGENT FOR MRI DIAGNOSTIC PROCEDURES
BRISTOL-MYERS SQUIBB COMPANY ANNOUNCES IN-LICENSING AGREEMENT FOR GASTROINTESTINAL CONTRAST AGENT FOR MRI DIAGNOSTIC PROCEDURES
BRISTOL-MYERS SQUIBB ANNOUNCES SALE
BRACCO, S.P.A., OF ITALY ACQUIRES DIAGNOSTICS DIVISION OF BRISTOL-MYERS SQUIBB
Bristol-Myers Squibb Medical Imaging and IMCOR Pharmaceutical enter into cross-licensing agreement for ultrasound contrast patents.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters